Antiangiogenic therapies in ovarian cancer

Item

http://www.wikidata.org/entity/Q28073722

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Antiangiogenic therapies in ovarian cancer

@ast

Antiangiogenic therapies in ovarian cancer

@en

Antiangiogenic therapies in ovarian cancer

@nl

type

Item

label

Antiangiogenic therapies in ovarian cancer

@ast

Antiangiogenic therapies in ovarian cancer

@en

Antiangiogenic therapies in ovarian cancer

@nl

prefLabel

Antiangiogenic therapies in ovarian cancer

@ast

Antiangiogenic therapies in ovarian cancer

@en

Antiangiogenic therapies in ovarian cancer

@nl

P1476

Antiangiogenic therapies in ovarian cancer

@en

P2093

Alexander Reinthaller

http://www.w3.org/2001/XMLSchema#string

P2860

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection

Rethinking ovarian cancer: recommendations for improving outcomes.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

P2888

s12254-016-0282-4

P304

139-143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3495147

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S12254-016-0282-4

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Reinthaller

P577

2016-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009151334

http://www.w3.org/2001/XMLSchema#string

P698

27752291

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5045478

http://www.w3.org/2001/XMLSchema#string